{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:21:51Z","timestamp":1769599311136,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,11]],"date-time":"2013-08-11T00:00:00Z","timestamp":1376179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00431-013-2125-1","type":"journal-article","created":{"date-parts":[[2013,8,10]],"date-time":"2013-08-10T06:33:51Z","timestamp":1376116431000},"page":"87-92","source":"Crossref","is-referenced-by-count":19,"title":["Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness"],"prefix":"10.1007","volume":"173","author":[{"given":"Astrid","family":"Bertsche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina P.","family":"Neininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna J.","family":"Dahse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Syrbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias K.","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Frontini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wieland","family":"Kiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilo","family":"Bertsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Merkenschlager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,11]]},"reference":[{"key":"2125_CR1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00148581-200709040-00007","volume":"9","author":"M Avner","year":"2007","unstructured":"Avner M, Finkelstein Y, Hackam D, Koren G (2007) Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale. Paediatr Drugs 9:267\u2013270","journal-title":"Paediatr Drugs"},{"key":"2125_CR2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1468-1331.2004.00992.x","volume":"12","author":"L Forsgren","year":"2005","unstructured":"Forsgren L, Beghi E, Oun A, Sillanp\u00e4\u00e4 M (2005) The epidemiology of epilepsy in Europe\u2014a systematic review. Eur J Neurol 12:245\u2013253","journal-title":"Eur J Neurol"},{"key":"2125_CR3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.seizure.2006.05.007","volume":"15","author":"T Gerstner","year":"2005","unstructured":"Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, Goetze G, Macke A, Lippert G, Klostermann W, Mayer G, Augspach-Hofmann R, Fitzek S, Haensch CA, Reuland M, Koenig SA (2005) Valproic acid induced encephalopathy\u201419 new cases in Germany from 1994 to 2003\u2014a side effect associated to VPA-therapy not only in young children. Seizure 15:443\u2013448","journal-title":"Seizure"},{"key":"2125_CR4","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1528-1167.2006.00846.x","volume":"47","author":"SA Koenig","year":"2006","unstructured":"Koenig SA, Buesing D, Longin E, Oehring R, H\u00e4ussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Br\u00fcckner R, Seitz R, Boxtermann W, Weber Y, Knapp R, Richard HH, Weidner B, Kasper JM, Haensch CA, Fitzek S, Hartmann M, Borusiak P, M\u00fcller-Deile A, Degenhardt V, Korenke GC, Hoppen T, Specht U, Gerstner T (2006) Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:2027\u20132031","journal-title":"Epilepsia"},{"key":"2125_CR5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MBC.0b013e3282f3f9ec","volume":"19","author":"S Koenig","year":"2008","unstructured":"Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE (2008) High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis 19:375\u2013382","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2125_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0404.2009.01257.x","volume":"121","author":"R Kuba","year":"2010","unstructured":"Kuba R, Novotn\u00e1 I, Br\u00e1zdil M, Kocvarov\u00e1 J, Tyrl\u00edkov\u00e1 I, Mast\u00edk J, Rektor I (2010) Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. Acta Neurol Scand 121:83\u201388","journal-title":"Acta Neurol Scand"},{"key":"2125_CR7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314\u2013319","journal-title":"N Engl J Med"},{"key":"2125_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.braindev.2010.03.002","volume":"33","author":"J Li","year":"2011","unstructured":"Li J, Xiao N, Chen S (2011) Efficacy and tolerability of levetiracetam in children with epilepsy. Brain Dev 33:145\u2013151","journal-title":"Brain Dev"},{"key":"2125_CR9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.yebeh.2009.09.024","volume":"16","author":"KM McVearry","year":"2009","unstructured":"McVearry KM, Gaillard WD, VanMeter J, Meador KJ (2009) A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav 16:609\u2013616","journal-title":"Epilepsy Behav"},{"key":"2125_CR10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","volume":"16","author":"KJ Meador","year":"2009","unstructured":"Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 16:1597\u20131605","journal-title":"N Engl J Med"},{"key":"2125_CR11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/brain\/awq352","volume":"134","author":"KJ Meador","year":"2011","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2011) Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 134:396\u2013404","journal-title":"Brain"},{"key":"2125_CR12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.0b013e318250d824","volume":"78","author":"KJ Meador","year":"2012","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2012) Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 78:1207\u20131214","journal-title":"Neurology"},{"key":"2125_CR13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244\u2013252","journal-title":"Lancet Neurol"},{"key":"2125_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1059-1311(03)00111-0","volume":"13","author":"M Mula","year":"2004","unstructured":"Mula M, Trimble MR, Sander JW (2004) Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 13:55\u201357","journal-title":"Seizure"},{"key":"2125_CR15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","volume":"61","author":"M Mula","year":"2003","unstructured":"Mula M, Trimble MR, Yuen A, Liu RS, Sander JW (2003) Psychiatric adverse events during levetiracetam therapy. Neurology 61:704\u2013706","journal-title":"Neurology"},{"key":"2125_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S1355617710001359","volume":"17","author":"C Nadebaum","year":"2011","unstructured":"Nadebaum C, Anderson V, Vajda F, Reutens D, Barton S, Wood A (2011) The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 17:133\u2013142","journal-title":"J Int Neuropsychol Soc"},{"key":"2125_CR17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.jcp.0000264973.77581.61","volume":"27","author":"J Nicolai","year":"2007","unstructured":"Nicolai J, Aldenkamp AP, Huizenga JR, Teune LK, Brouwer OF (2007) Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy. J Clin Psychopharmacol 27:221\u2013224","journal-title":"J Clin Psychopharmacol"},{"key":"2125_CR18","doi-asserted-by":"crossref","first-page":"CR203","DOI":"10.12659\/MSM.881716","volume":"17","author":"E Pronicka","year":"2011","unstructured":"Pronicka E, Weglewska-Jurkiewicz A, Pronicki M, Sykut-Cegielska J, Kowalski P, Pajdowska M, Jankowska I, Kotulska K, Kalicinski P, Jakobkiewicz-Banecka J, Wegrzyn G (2011) Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Med Sci Monit 17:CR203\u2013CR209","journal-title":"Med Sci Monit"},{"key":"2125_CR19","first-page":"663","volume":"55","author":"M Raspall-Chaure","year":"2012","unstructured":"Raspall-Chaure M, Lainez E, Toledo M, Salas-Puig J, Macaya-Ruiz A, Roig-Quilis M (2012) Reversible encephalopathy caused by valproic acid in an adolescent with idiopathic generalised epilepsy. Rev Neurol 55:663\u2013668","journal-title":"Rev Neurol"},{"key":"2125_CR20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/jnnp-2011-301999","volume":"83","author":"F Rosenow","year":"2012","unstructured":"Rosenow F, Schade-Brittinger C, Burchardi N, Bauer S, Klein KM, Weber Y, Lerche H, Evers S, Kovac S, Hallmeyer-Elgner S, Winkler G, Springub J, Niedhammer M, Roth E, Eisensehr I, Berrouschot J, Arnold S, Schr\u00f6der M, Beige A, Oertel WH, Strzelczyk A, Haag A, Reif PS, Hamer HM, LaLiMo Study Group (2012) The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy\u2014an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry 83:1093\u20131098","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2125_CR21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1212\/WNL.0b013e3182088297","volume":"76","author":"R Shallcross","year":"2011","unstructured":"Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA, Liverpool Manchester Neurodevelopment Group, UK Epilepsy and Pregnancy Register (2011) Child dev following in utero expo: levetiracetam vs sodium valproate Neurol. Neurology 76:383\u2013389","journal-title":"Neurology"},{"key":"2125_CR22","author":"E Trinka","year":"2012","unstructured":"Trinka E, Marson AG, Van Paesschen W, K\u00e4lvi\u00e4inen R, Marovac J, Duncan B, Buyle S, Hallstr\u00f6m Y, Hon P, Muscas GC, Newton M, Meencke HJ, Smith PE, Pohlmann-Eden B, for the KOMET Study Group (2012) KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. doi: 10.1136\/jnnp-2011-300376","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2125_CR23","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrneurol.2012.184","volume":"8","author":"H Wood","year":"2012","unstructured":"Wood H (2012) Epilepsy: psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signaling. Nat Rev Neurol 8:532","journal-title":"Nat Rev Neurol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-013-2125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-013-2125-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-013-2125-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:22:23Z","timestamp":1559082143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-013-2125-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,11]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2125"],"URL":"https:\/\/doi.org\/10.1007\/s00431-013-2125-1","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,11]]}}}